228 related articles for article (PubMed ID: 37440421)
1. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
[TBL] [Abstract][Full Text] [Related]
2. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Underwood PW; Cloyd JM
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38568860
[No Abstract] [Full Text] [Related]
3. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.
Kim HS; Lee M; Han Y; Kang JS; Kang YH; Sohn HJ; Kwon W; Lee DH; Jang JY
J Hepatobiliary Pancreat Sci; 2023 Jul; 30(7):924-934. PubMed ID: 36652346
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
7. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
[TBL] [Abstract][Full Text] [Related]
8. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival.
Rose JB; Edwards AM; Rocha FG; Clark C; Alseidi AA; Biehl TR; Lin BS; Picozzi VJ; Helton WS
Oncologist; 2020 Oct; 25(10):859-866. PubMed ID: 32277842
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
10. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
[TBL] [Abstract][Full Text] [Related]
11. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
[TBL] [Abstract][Full Text] [Related]
12. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma.
Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Pancreatology; 2023 Dec; 23(8):970-977. PubMed ID: 37914628
[TBL] [Abstract][Full Text] [Related]
13. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
15. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
[TBL] [Abstract][Full Text] [Related]
16. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
Tachezy M; Gebauer F; Petersen C; Arnold D; Trepel M; Wegscheider K; Schafhausen P; Bockhorn M; Izbicki JR; Yekebas E
BMC Cancer; 2014 Jun; 14():411. PubMed ID: 24906700
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
Liu S; Li H; Xue Y; Yang L
PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
19. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
